Su Xiaojun, Yan Xiuli, Zhang Hui
Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200437, China.
Mol Cancer. 2025 Jun 10;24(1):173. doi: 10.1186/s12943-025-02378-8.
Hepatocellular carcinoma (HCC) progression and therapeutic resistance are profoundly influenced by the dynamic interplay within the tumor microenvironment (TME). The HCC TME comprises a complex network of cellular components, including cancer-associated fibroblasts, tumor-associated macrophages, and infiltrating immune cells, alongside non-cellular factors such as extracellular matrix proteins, cytokines, and angiogenic mediators. These elements collectively promote immune evasion, stromal remodeling, and neovascularization, driving tumor aggressiveness and treatment resistance. Emerging evidence suggests that traditional Chinese medicine (TCM) may offer a promising strategy to reprogram the immunosuppressive HCC TME through multimodal mechanisms, such as immunomodulation to enhance anti-tumor immunity and deplete regulatory cell populations, stromal normalization to attenuate fibroblast activation and pathological matrix deposition, and anti-angiogenic effects to restrict tumor vascularization. Notably, TCM compounds exhibit synergistic potential when combined with conventional therapies, including immune checkpoint inhibitors, tyrosine kinase inhibitors, and cytotoxic regimens, potentially enhancing efficacy while mitigating adverse effects. However, key challenges persist, such as intratumoral heterogeneity, pharmacokinetic variability of herbal formulations, and the need for rigorous preclinical-to-clinical translation. Future investigations should prioritize systems-level dissection of TCM-mediated TME modulation using omics technologies, rational design of TCM-based combination therapies guided by mechanistic studies, and standardization of clinically translatable TCM regimens. This review synthesizes current understanding of TME-driven HCC pathogenesis and highlights the emerging paradigm of TCM as a complementary modality to recalibrate the tumor-immune-stroma axis for improved therapeutic outcomes.
肝细胞癌(HCC)的进展和治疗耐药性受到肿瘤微环境(TME)中动态相互作用的深刻影响。HCC的TME由细胞成分的复杂网络组成,包括癌症相关成纤维细胞、肿瘤相关巨噬细胞和浸润免疫细胞,以及细胞外基质蛋白、细胞因子和血管生成介质等非细胞因子。这些成分共同促进免疫逃逸、基质重塑和新血管形成,推动肿瘤侵袭性和治疗耐药性。新出现的证据表明,传统中医药(TCM)可能提供一种有前景的策略,通过多模式机制重新编程免疫抑制性的HCC TME,如免疫调节以增强抗肿瘤免疫力和消耗调节性细胞群体、基质正常化以减弱成纤维细胞活化和病理性基质沉积,以及抗血管生成作用以限制肿瘤血管形成。值得注意的是,中药化合物与包括免疫检查点抑制剂、酪氨酸激酶抑制剂和细胞毒性方案在内的传统疗法联合使用时具有协同潜力,可能提高疗效同时减轻不良反应。然而,关键挑战仍然存在,如肿瘤内异质性、草药制剂的药代动力学变异性,以及从临床前到临床严格转化的必要性。未来的研究应优先使用组学技术对中药介导的TME调节进行系统层面的剖析,以机制研究为指导合理设计基于中药的联合疗法,并标准化可临床转化的中药方案。本综述综合了目前对TME驱动的HCC发病机制的理解,并强调了中药作为一种补充方式重新校准肿瘤-免疫-基质轴以改善治疗结果的新兴模式。